1
Kevin Rodzinak
Donna J Armstrong, Essa H Hu, Michael J Kelly III, Mark E Layton, Yiwei Li, Jun Liang, Kevin J Rodzinak, Michael J Rossi, Philip E Sanderson, Jiabing Wang: Inhibitors of akt activtiy. Merck Sharp & Dohme, Matthew A Leff, David A Mutard, August 30, 2011: US08008317 (4 worldwide citation)

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


2

3
Kevin Rodzinak
Hidetomo Furuyama, Yasuhiro Goto, Nobuhiko Kawanishi, Mark E Layton, Takashi Mita, Akira Naya, Yoshio Ogino, Yu Onozaki, Kevin J Rodzinak, Toshihiro Sakamoto, Philip E Sanderson, Jiabing Wang: Inhibitors of akt activity. April 21, 2011: US20110092511-A1

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms, preferably Akt1. The invention also provides for compositions comprising such inhibitory compounds and methods ...


4
Kevin Rodzinak
Donna J Armstrong, Essa H Hu, Michael J Kelly III, Mark E Layton, Yiwei Li, Jun Liang, Kevin J Rodzinak, Michael A Rossi, Philip E Sanderson, Jiabing Wang: Inhibitors of akt activtiy. Merck, September 2, 2010: US20100222321-A1

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


5
Ben C Askew, Paul J Coleman, Mark E Duggan, Wasyl Halczenko, John H Hutchinson, Robert S Meissner, Michael A Patane, Jiabing Wang: Integrin receptor antagonists. Merck & Co, Philippe L Durette, Melvin Winokur, Anthony D Sabatelli, January 25, 2000: US06017926 (23 worldwide citation)

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5 and/or .alpha.v.beta.6 and are use ...


6
Ben C Askew, Paul J Coleman, Mark E Duggan, Wasyl Halczenko, George D Hartman, Cecilia A Hunt, John H Hutchinson, Robert S Meissner, Michael A Patane, Garry R Smith, Jiabing Wang: Integrin receptor antagonists. Merck & Co, Philippe L Durette, Melvin Winokur, Anthony Sabatelli, April 11, 2000: US06048861 (17 worldwide citation)

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5, and/or .alpha.v.beta.6 and are us ...


7
Mark E Duggan, Wasyl Halczenko, John H Hutchinson, Aiwen Li, Robert S Meissner, James J Perkins, Thomas G Steele, Jiabing Wang, Michael A Patane: &agr;V integrin receptor antagonists. Merck & Co, Patricia A Shatynski, Mark R Daniel, October 29, 2002: US06472403 (5 worldwide citation)

The present invention relates to novel imidazolidinone derivatives thereof, their synthesis, and their use as &agr;v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors &agr;v&bgr;3 and/or &agr;v&bgr;5 and are useful for ...


8
Barbara Hanney, Yuntae Kim, Michael R Krout, Robert S Meissner, Helen J Mitchell, Jeffrey Musselman, James J Perkins, Jiabing Wang: N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators. Merck & Co, Patricia A Shatynski, Curtis C Panzer, September 11, 2007: US07268153 (4 worldwide citation)

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, inc ...


9
Jiabing Wang: Alpha v integrin receptor antagonists. Merck & Co, Patricia A Shatynski, Mark R Daniel, June 6, 2006: US07056909 (4 worldwide citation)

The present invention relates to novel chain-fluorinated alkanoic acid derivatives thereof, their synthesis, and their use as αv integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors αvβ3 and/or αvβ5 and are useful for inhi ...


10
Ben C Askew, Paul J Coleman, Mark E Duggan, Wasyl Halczenko, George D Hartman, Cecilia A Hunt, John H Hutchinson, Robert S Meissner, Michael A Patane, Garry R Smith, Jiabing Wang: Integrin receptor antagonists. Merck & Co, Patricia A Shatynski, Mark R Daniel, August 31, 2004: US06784190 (3 worldwide citation)

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors &agr;v&bgr;3, &agr;v&bgr;5, and/or &agr;v&bgr;6 and are useful for ...



Click the thumbnails below to visualize the patent trend.